QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.105.097584v1 jpet.105.097584v2 317/3/989    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wen, D. Articles by Xu, Y. Search for Related Content PubMed PubMed Citation Articles by Wen, D. Articles by Xu, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

A Selective Small Molecule IB Kinase Inhibitor Blocks Nuclear Factor B-Mediated Inflammatory Responses in Human Fibroblast-Like Synoviocytes, Chondrocytes, and Mast Cells

Departments of Inflammation and Discovery Technologies, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts

Received October 25, 2005; accepted March 6, 2006.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
IB kinase (IKK) is essential for inflammatory cytokine-induced activation of nuclear factor B (NF-B). NF-B plays a pivotal role in the function of major cell types that contribute to the pathophysiological process of rheumatoid arthritis (RA). Here, we report the mechanism and the effect of the IKK inhibitor N-(6-chloro-7-methoxy-9H--carbolin-8-yl)-2-methylnicotinamide (ML120B), a -carboline derivative, on NF-B signaling and gene activation in RA-relevant cell systems. ML120B is a potent, selective, reversible, and ATP-competitive inhibitor of IKK with an IC₅₀ of 60 nM when evaluated in an IB kinase complex assay. ML120B does not inhibit other IKK isoforms or a panel of other kinases. ML120B concentration-dependently inhibits tumor necrosis factor (TNF)-stimulated NF-B signaling via inhibition of IB phosphorylation, degradation, and NF-B translocation into the nucleus. For the first time, we have demonstrated that in human fibroblast-like synoviocytes, TNF- or interleukin (IL)-1-induced monocyte chemoattractant protein-1 regulated on activation, normal T cell expressed and secreted and production is IKK-dependent. In addition, for the first time, we have demonstrated that lipopolysaccharide- or peptidoglycan-induced cytokine production in human cord blood-derived mast cells is IKK-dependent. In addition, in human chondrocytes, ML120B inhibited IL-1-induced matrix metalloproteinase production with an IC₅₀ of approximately 1 µM. ML120B also blocked IL-1-induced prostaglandin E₂ production. In summary, ML120B blocked numerous NF-B-regulated cell responses that are involved in inflammation and destructive processes in the RA joint. Our findings support the evaluation of IKK inhibitors as anti-inflammatory agents for the treatment of RA.

Rheumatoid arthritis is a chronic destructive disease of the joints, characterized by inflammation, synovial hyperplasia, and abnormal cellular and humoral immune responses. Several cell types have been implicated as major contributors in the pathophysiological process of RA (Gravallese, 2002), including fibroblast-like synoviocytes (FLS), macrophages, T cells, B cells, osteoclasts, chondrocytes, dendritic cells, and mast cells. Specific cytokines, chemokines, and tissue-destructive enzymes have been identified as key players in the pathologic process of RA. Multiple lines of evidence suggest that NF-B plays a key role in regulating the inflammatory process in these cell types. Therefore, identification of selective IKK inhibitors as potential therapeutics has received considerable interest.

Here, we report that ML120B is a potent and selective IKK inhibitor. We have examined cellular mechanisms and functional effects of ML120B in RA-relevant cell systems. Our results demonstrate that ML120B specifically blocked the NF-B signaling pathway. ML120B concentration-dependently blocked LPS-, TNF-, or IL-1-stimulated cytokine production in inflammatory cells, including human peripheral blood mononuclear cells (PBMC), human fibroblast-like synoviocytes (HFLS), and human mast cells (MC). ML120B also blocked IL-1-stimulated collagenases (MMP1, MMP13), stromelysin (MMP3), and prostaglandin E₂ (PGE₂) production in the human chondrocyte cell line SW1353. Taken together, these results suggest a potential use of this class of compounds as therapeutic agents in the treatment of RA.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Reagents. Nonidet P-40, Triton X-100, Tween 20, BSA, LPS (Escherichia coli O26:B6), DMSO, toluidine blue, PMA, ionomycin, and PGN were purchased from Sigma-Aldrich (St. Louis, MO). CD3 and CD28 were obtained from BD Biosciences (San Jose, CA). rhTNF, rhIL-1, IL-4, and IL-6 were obtained from R&D Systems (Minneapolis, MN). Phospho-IB (Ser32/36) (12C2) monoclonal antibody was purchased from Cell Signaling Technologies (Beverly, MA) and labeled with W8044 europium chelate by PerkinElmer Life and Analytical Sciences (Boston, MA). Streptavidin Alexa 647 and Blasticidin were purchased from Invitrogen (Carlsbad, CA). GST-IB (5–55) was produced in E. coli as described previously (Chen et al., 1996; Lee et al., 1997, 1998) and labeled with biotin using PEO-Maleimide Activated Biotin from Pierce (Rockford, IL) as per the manufacturer's instructions. Titertube deep-well 96-well plates were purchased from Bio-Rad (Hercules, CA). PE-conjugated anti-human TLR antibodies were from eBioscience (San Diego, CA).

Compounds. -Carboline compounds ML120B and PS1145 were synthesized at Millennium Pharmaceuticals, Inc. (Cambridge, MA). In all cell-based assays, compounds were preincubated with cells for 30 min or 1 h before stimulation. The compound was dissolved in DMSO. The final concentration of DMSO in all the assays was 0.5%.

Cell Lines. The 293 NF-B-Luc and 293 AP-1-Luc reporter stable cell lines were generated at Millennium Pharmaceuticals, Inc. Briefly, the construct of NF-B-TA-Luc or AP-1-Luc engineered with a Blasticidin selection gene was used to stably transfect the 293 cell line. Positive clones were selected using Blasticidin and evaluated by their responsiveness to TNF or PMA/ionomycin stimulation. HFLS were obtained from Cell Applications, Inc. (San Diego, CA). Human chondrosarcoma cells SW1353 and HeLa cells were purchased from American Type Culture Collection (Manassas, VA).

Human Plasma. Normal human blood was obtained through Millennium Pharmaceuticals, Inc.'s blood donation program. Normal human plasma was pooled from multiple donors, and aliquots were stored at –80°C.

Preparation of IKK Complex. The IKK complex was purified and activated as described previously (Chen et al., 1996; Lee et al., 1997, 1998) with minor modifications. HeLa cell S100 lysates were precipitated in 30% ammonium sulfate and resuspended in buffer A (50 mM Hepes, pH 7.5, 100 mM NaCl, 10 mM 2-glycerophosphate, 2 mM dithiothreitol, and 0.5 mM EDTA) and were passed over a Superose 6 gel filtration column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) pre-equilibrated in buffer A. Fractions containing IKK activity were pooled and activated with 100 nM recombinant MEKK1 at 37^°C for 45 min in buffer A supplemented with 10 mM MgCl₂, 250 µM ATP, and 2 µM Microcystin-LR (Sigma-Aldrich).

IKK Complex Enzyme Assay. Phosphorylation of GST-IB (5–55) was measured by incubating test samples in 3% DMSO with activated IKK complex as described above: 300 nM GST-IB (5–55) and varying ATP concentrations in 50 mM Hepes, pH 7.5, 10 mM 2-glycerophosphate, 10 mM MgCl₂, 5 mM dithiothreitol, and 0.1% BSA were incubated in a reaction volume of 30 µl for 1 h at room temperature. Reactions were terminated with the addition of 10 µlof 250 mM EDTA, followed by the addition of 40 µl of detection mixture containing 2 nM europium-labeled anti-phospho IB and 50 nM streptavidin Alexa 647 in 50 mM Hepes, pH 7.5, 0.1% BSA, and 0.01% Tween 20. After 1 h, plates were read on a Wallac Victor plate reader (PerkinElmer Life and Analytical Sciences).

IKK Complex Reversibility Assay. IKK complex was incubated for 1 h with 10 µM ML120B. After incubation, samples were passed through a Zeba gel filtration column (Pierce) according to manufacturer's instructions. Samples were assayed as described above but at an ATP concentration of 1 mM.

IKK Kinase Assays. Recombinant IKK (Upstate Biotechnology, Lake Placid, NY) was assayed under identical conditions as the IKK complex assay with the following modifications. IKK (1 nM) was substituted for activated IKK complex, and the ATP concentration was adjusted to 1 µM.

Kinase Selectivity Assays. All kinase selectivity assays were performed against recombinant kinases at or below the K_m of ATP. Assays against IKK were performed through Upstate Kinase Profiler (Upstate Biotechnology). Assays against PKC, PKC, PKC, CSK, Src, and Lyn were performed in a time-resolved fluorescence format. All other assays were performed in Flashplate assays (PerkinElmer Life and Analytical Sciences).

Western Blot. HeLa cells or human PBMCs were preincubated with ML120B or DMSO for 1 h before the stimulation with TNF (50 ng/ml) for 5 or 20 min. Cells were lysed using whole cell lysis buffer, and protein concentrations were determined using a bicinchoninic acid kit (Pierce). Twenty micrograms of cell lysate was loaded into each well of a 4 to 12% NuPAGE Bis-Tris gradient gel (Invitrogen). The blot was blocked in 5% milk/phosphate-buffered saline/Tween 20 and incubated with polyclonal anti-phosphorylated IB antibody or polyclonal anti-IB antibody (Cell Signaling) and, subsequently, anti-rabbit secondary antibody (Cell Signaling). ECL Plus (GE Healthcare, Little Chalfont, Buckinghamshire, UK) was used for detection.

HeLa Cells in NF-B Nuclear Translocation Assay. HeLa cells were maintained in Dulbecco's modified Eagle's media with 10% FBS, 2 mM glutamine, and 1% penicillin/streptomycin solution. The effect of ML120B on the nuclear translocation of p65, in response to stimulus, was examined by using high-content screening technology from Universal Imaging Corporation (Downingtown, PA). Briefly, HeLa cells were seeded into a 96-well black, clear-bottom Packard ViewPlate at 5000 cells/per well the day before the experiment. ML120B was serially diluted 1:1 in DMSO with final concentrations ranging from 20 to 0.04 µM. After a 1-h preincubation with ML120B, cells were stimulated with TNF (10 ng/ml) for 30 min, fixed with 4% paraformaldehyde solution, and permeabilized with 0.5% Triton X-100. After being washed with 0.5% phosphate-buffered saline, cells were blocked with 0.5% blocking reagent (Roche, Indianapolis, IN). Furthermore, cells were stained using "Cellomics Hit Kit" (Cellomics, Pittsburgh, PA) for the detection of NF-B activation following the kit manual. Images were acquired with Discovery-1 system, and nuclear translocation data were analyzed by MetaMorph Software from Universal Imaging Corporation.

NF-B DELFIA Assay. To quantitatively measure NF-B binding activity upon activation, we developed an NF-B DELFIA assay based on the Trans-AM NF-B assay kit (Active Motif, Carlsbad, CA). Cells were plated in a 96-well plate the day before the experiment. After preincubation with serially diluted ML120B at 37°C for 1 h, cells were stimulated with TNF (10 ng/ml) at 37°C for 30 min. Whole cell extract was prepared from the cell pellet. Twenty micrograms of whole cell extract was added in duplicate into a 96-well Trans-AM NF-B plate containing the immobilized NF-B consensus site (5'-GGGACTTTCC-3'). After a 1-h incubation with the primary antibody, wells were washed with DELFIA wash buffer (PerkinElmer Life and Analytical Sciences) and incubated with Eu-N1-labeled anti-mouse IgG (PerkinElmer Life and Analytical Sciences) for DELFIA readout. The NF-B activation was quantified as europium counts of time-resolved fluorometry on a Wallac Victor plate reader.

NF-B or AP-1 Luciferase Reporter Assay. 293/NF-B-Luc and 293/AP-1-Luc cells were maintained in DMEM (Invitrogen) with 10% FBS (Hyclone, Logan, UT), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 5 µg/ml Blasticidin (Invitrogen). Cells were seeded at a density of 0.05 x 10⁶ cells per well in black poly-D-lysine 96-well plates (Discovery Labware Inc., Bedford, MA) the day before the assay. ML120B or PS1145 was serially diluted 1:1 in DMSO to produce concentrations ranging from 20 to 0.04 µM. Medium was changed to AIM-V (Invitrogen) for the assay. Cells were preincubated with IKK inhibitor (ML120B or PS1145) for 1 h at 5% CO₂ at 37°C. For the NF-B assay, cells were stimulated with 0.5 ng/ml TNF (R&D Systems) or 10 pg/ml PMA and 2 µM ionomycin for 3 h. For the AP-1 assay, cells were stimulated with 10 pg/ml PMA and 2 µM ionomycin for 3 h. Medium was removed, and cells were lysed in 1x passive lysis buffer (GE Healthcare). Lysate (20 µl) was used in accordance with luciferase assay kit (Promega, Madison, WI). The assay was run in triplicate, and data were analyzed using XLfit software (IDBS Ltd., Guildford, UK).

Transient Transfection Assays Using Luciferase Reporter Panel. The following PathDetect cis-reporter luciferase plasmids were purchased from Stratagene (La Jolla, CA): NF-B, AP-1, cAMP response element, serum response element, interferon-stimulated response element, and nuclear factor of activated T cells. The IL-8-luciferase reporter was obtained from the A. Casola laboratory and contains the promoter region of IL-8 (–162 to +44) upstream of the luciferase gene (Casola et al., 2000) The ELAM-luciferase reporter was generated in-house and contains the promoter region of the human E-Selectin gene from –730 to +52 cloned into a modified TATA-less version of pMCS-Luc (Stratagene). Transient transfection and assay of ML120B and PS1145 on the luciferase reporter panel was carried out as follows: 293T cells were plated at a density of 17,000 cells per well in 100 µl of culture medium (DMEM, 10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine) in Biocoat poly-D-lysine 96-well plates (Becton Dickinson, San Jose, CA). The following day, cells were transfected with a cocktail containing 100 ng of DNA consisting of 50 ng of luciferase reporter DNA, 5 ng of internal control pTK-Renilla (Promega), and 45 ng of empty vector using Fugene transfection reagent (Roche) following the manufacturer's instructions. After overnight incubation, fresh medium containing 0.1% FBS was added to the plates, and cells were incubated overnight. Cells were preincubated with IKK inhibitor compounds (ML120B or PS1145 prepared in DMSO) added at a dose range from 10 nM to 31.6 µM (3-fold serial dilution), and 30 min later, various stimulants for the reporters were added to induce the different pathways being monitored: 50 ng/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin (Sigma-Aldrich), 20 µM forskolin (Sigma-Aldrich), 1000 U/ml interferon- (R&D Systems), and 50 ng/ml TNF (R&D Systems). The cells were incubated for a further 6.5 h, after which cells were harvested and luciferase values were measured using the dual luciferase assay kit (Promega). Each individual assay was performed in quadruplicate per experiment, and the complete transfection procedure for the reporter panel was performed a minimum of two times. The data were analyzed using XLfit software.

Human PBMC Assay. Heparinized human whole blood was obtained from normal donors. PBMCs were separated on a Ficoll-Paque Plus (GE Healthcare) gradient. Compound was serially diluted 1:1 in DMSO with final concentrations ranging from 20 to 0.04 µM. Cells at a density of 4 x 10⁵ per well were seeded in a 96-well plate and incubated at 5% CO₂ at 37°C. Cells were preincubated with compound for 1 h and then stimulated with either LPS (100 ng/ml) or CD3 (0.25 µg/ml) and CD28 (0.25 µg/ml) for 5 h. Supernatant was collected for cytokine analysis.

Cytokine Analysis. Quantitative measurement of cytokines in culture supernatant or plasma was performed by Pierce Biotechnology, Inc. (Woburn, MA) using the SearchLight Human Cytokine Array, a multiplexed sandwich enzyme-linked immunosorbent assay (ELISA).

Cytotoxicity Lactate Dehydrogenase Release Assay. Compound cytotoxicity was monitored by the measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the supernatant. The supernatant from human PBMC assays was tested for LDH release following the vendor's kit manual (Roche). Triton X-100-treated cells (2%) are used to determine the maximum releasable LDH activity in the cells. Cells treated with 0.5% DMSO were used to determine the basal level of LDH activity.

HFLS Assay. Cryopreserved HFLS cells were thawed and cultured in synoviocyte growth culture medium (Cell Applications, Inc., San Diego, CA). After two to three rounds of subculture, 1 x 10⁵ cells per well were plated in black poly-D-lysine 96-well plates (Discovery Labware, Inc.) 1 day before the experiment. ML120B was serially diluted 1:1 with DMSO and preincubated with the cells at 5% CO₂ at 37°C for 1 h. For cytokine studies, the cells were stimulated with 10 ng/ml human TNF or 10 ng/ml human IL-1 and cultured for 16 h. The supernatant was harvested and analyzed for RANTES, MCP-1, IL-6, and IL-8 production (Pierce Biotechnology, Inc.). To measure the effects of ML120B on NF-B activation, the cells were stimulated with either IL-1 (10 ng/ml) or TNF (10 ng/ml) for 30 min. Whole cell extract was used to measure of NF-B activation by the NF-B DELFIA assay as described above, except that compound was serially diluted 1:1 in DMSO with final concentrations ranging from 50 to 0.1 µM.

Human Cord Blood-Derived Mast Cells Assay. Human PBMCs were separated by Ficoll (GE Healthcare) gradient from human cord blood (Cambrex Bio Science, Walkersville, Maryland) and then cultured in mast cell culture medium (RPMI 1640 containing 10% fetal bovine serum 2 mM L-glutamine, 0.1 mM nonessential amino acid, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 µg/ml gentamycin, and 0.2 µM 2-mercaptoethanol) in the presence of 100 ng/ml human stem cell factor (R&D System), 10 ng/ml human IL-6, and 10 ng/ml human IL-10. Nonadherent cells were transferred to a new flask containing mast cell culture medium with fresh cytokines every week. To assess the maturity of the mast cells, starting from week 6, an aliquot of cells was stained with toluidine blue, and the expression of c-Kit (BD Bioscience, San Jose, CA) was analyzed by FACS. When >95% of the cells were confirmed to have differentiated into mature mast cells, the cells were processed for pharmacology studies. The cells were preincubated with serially diluted ML120B at 5% CO₂ at 37°C for 1 h and then stimulated with 10 ng/ml LPS or 100 µg/ml PGN overnight. The supernatant was collected and subjected to cytokine profiling analysis (Pierce Biotechnology, Inc.).

Expression of Toll-Like Receptors on Human Cord Blood-Derived Mast Cells. Mast cells (0.5 x 10⁵) were washed with ice-cold 1x phosphate-buffered saline with 1% BSA. Cells were stained with PE-conjugated anti-human TLR 2, TLR 4, TLR 3, or TLR 9 antibodies, respectively. PE-conjugated mouse IgG or PE-conjugated rat IgG2 was used as epitope controls. The expression of TLRs on mast cell surface was analyzed by FACS.

Adenovirus Transduction of IKK wt, IKK DN, and IBSR in Human Mast Cells. The recombinant adenovirus constructs carrying the IKK wild type (IKK wt), IKK dominant-negative (IKK DN K44M), and IB super-repressor (IB SR) were kindly provided by Philip A. Barker (McGill University, Montreal, QC, Canada; Bhakar et al., 2002). Transduction efficiency was monitored by GFP expression. Mast cells were seeded in 24-well culture plate at 2 x 10⁵ per well. Adenovirus titer m.o.i. was optimized in a pilot experiment so that all the wells would have similar transduction efficiency. After a 24-h infection with corresponding adenoviruses, cells were stimulated with either purified LPS at 50 ng/ml (gift from Dr. Kate Fitzgerald, University of Massachusetts Medical School, Worcester, MA) or PGN at 100 µg/ml for 16 h. The supernatant was collected and subjected to cytokine profiling analysis (Pierce Biotechnology, Inc.).

Human Chondrocyte SW1353 Assay. The human chondrosarcoma cell line SW1353 was cultured in DMEM with 2 mM Glutamax (Invitrogen), 100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and 10% fetal bovine serum (Hyclone, Logan, UT). Cells per well (0.05 x 10⁶) were seeded into a 96-well poly-D-lysine plate (Discovery Labware, Inc.) 1 day before the experiment. The culture medium was changed to fresh AIM-V medium containing 2% fetal calf serum on the day of the experiment. Serially diluted ML120B in DMSO, ranging from 20 to 0.02 µM, was preincubated with cells for 1 h at 5% CO₂ at 37°C and then stimulated with 10 ng/ml human IL-1 (R&D System) for 24 h. The supernatant was harvested and used to measure MMP1, MMP3, MMP13, and PGE₂ production by ELISA (GE Healthcare).

Statistical Analyses. The IC₅₀ assays were run in triplicate, and XLfit software was used to fit dose response curves to the mean values. The IC₅₀ values and their 95% confidence intervals were calculated with equation 205 (Sigmoidal dose-response model). Differences between IC₅₀ estimates were assumed significant at p = 0.05 if the 95% confidence intervals of the estimates did not overlap. Where appropriate, differences in means were assessed using Student's t test in Microsoft Excel. All p values were two-tailed and were considered significant when p 0.01. Results are expressed as the mean ± S.D. of a representative experiment.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Identification of ML120B as a Potent and Specific Inhibitor of IKK. In an earlier report, we described -carboline PS1145 as an IKK inhibitor with a certain level of specificity and potency (Fig. 1A) (Castro et al., 2003). Further chemical optimization has led to the identification of ML120B as a more potent and selective IKK inhibitor (Fig. 1B). ML120B was determined to have an IC₅₀ of 60 nM at 50 µM ATP in a time-resolved fluorescence assay measuring the phosphorylation of IB at various inhibitor concentrations in an in vitro kinase assay using IKK complex purified from HeLa cells and GST-IB as a substrate (Fig. 2A). Kinetic analysis shows ML120B to be a competitive inhibitor of ATP, as indicated by the double-reciprocal plots of velocity versus ATP concentration at fixed inhibitor concentrations (Fig. 2B). ML120B was also shown to be a reversible inhibitor of the IKK complex (Fig. 2C). To confirm that the activity of ML120B was indeed targeting IKK, an in vitro kinase assay was run using recombinant IKK. ML120B was determined to have an IC₅₀ of 45 ± 1 nM (95% confidence interval) against recombinant IKK (Fig. 2D).

View larger version (16K): [in this window] [in a new window]   Fig. 1. Chemical structures of -carboline compounds. A, PS1145. B, ML120B.

View larger version (20K): [in this window] [in a new window]   Fig. 2. ML120B is a potent, reversible, and ATP-competitive inhibitor of IKK. A, dose-dependent inhibition of IKK complex by ML120B. Inhibition of activated IKK complex by ML120B at 50 µM ATP using biotinylated GST-tagged IB (5–55) as a substrate. The data represent the average of triplicate measurements with error bars indicating standard deviations. See Materials and Methods for details. B, ML120B is an ATP-competitive inhibitor of the IKK complex. Phosphorylation of biotinylated GST-tagged IB (5–55) was measured at fixed inhibitor concentrations of 167 µM (closed squares), 111 µM (closed triangles), 75 µM (closed diamonds), 50 µM (closed circles), 33 µM (open squares), 22 µM (open triangles), and 0 µM (open diamonds). C, ML120B is a reversible inhibitor of the IKK complex. IKK enzyme alone or preincubated with 10 µM ML120B was passed through a desalting column and assayed for activity. One hundred percent activity was recovered from the preincubated sample compared with IKK with 10 µM ML120B added after desalting. D, ML120B specifically inhibits recombinant IKK. The data represent the average of triplicate measurements with error bars indicating standard deviations. See Materials and Methods for details.

To examine the selectivity of ML120B, inhibitory activities of MN120B were evaluated against a panel of 30 tyrosine and serine/threonine kinases, including IKK and IKK. As shown in Table 1, no inhibition below 50 µM was observed across this panel of kinases, thus demonstrating the selectivity of ML120B for IKK. ML120B was also screened at 10 µM against a NovaScreen (Hanover, MD) panel of 33 receptors, transporters, and channels. ML120B showed >100-fold selectivity over this panel (data not shown). To further evaluate the selectivity of ML120B, both ML120B and PS1145 were screened against a panel of eight luciferase reporters that represent different well characterized cellular pathways (Table 2). ML120B showed an inhibitory effect only on the NF-B reporter or reporters that contained an NF-B element in their promoter regions (IL-8 and ELAM). These data confirm that compared with the first generation -carboline compound PS1145, ML120B is a selective IKK inhibitor specific to the NF-B pathway.

ML120B Blocks NF-B Signaling Pathway. Upon activation by cellular stimuli, IKK phosphorylated IB. Phosphorylated IB was rapidly degraded through ubiquitin-dependent pathways, which allowed released NF-B factor to translocate to the nucleus and activate NF-B-mediated gene expression. To dissect how ML120B exerts its effect on the NF-B signaling pathway, we examined the effect of the IKK inhibitor on TNF-induced IB phosphorylation and IB degradation in HeLa cells. TNF stimulation causes IB phosphorylation within 5 to 10 min and IB degradation within 10 to 30 min after stimulation. ML120B blocked TNF-stimulated IB phosphorylation and degradation concentration-dependently when assessed by Western blot analysis (Fig. 3). To examine the effects of ML120B on NF-B translocation and DNA binding activity, we used high-content image analysis to measure and quantify nuclear translocation of p65 in the absence or presence of ML120B on HeLa cells. As indicated in Fig. 4A, ML120B concentration-dependently blocked TNF-induced nuclear translocation of p65 with an IC₅₀ of 2.4 µM (Fig. 4B). Furthermore, ML120B blocked TNF-induced NF-B-linked luciferase reporter activity in a concentration-dependent manner with an IC₅₀ of 1.1 µM (95% confidence interval: 0.9, 1.3) (Fig. 5A). However, ML120B showed minimal inhibition of PMA/ionomycin-induced AP-1-linked luciferase activity, as shown in Fig. 5A. In contrast, the first-generation -carboline compound PS1145 inhibited AP-1 luciferase reporter activity with an IC₅₀ of 8.8 ± 2.9 µM (95% confidence interval). For comparison, PS1145 concentration-dependently inhibited NF-B luciferase activity with an IC₅₀ of 1.7 µM (95% confidence interval: 5.9, 11.7) (Fig. 5B). Given these confidence intervals, PS1145 was significantly more potent against NF-B than AP-1; however, ML120B is more selective and more potent than the first generation compound PS1145.

View larger version (34K): [in this window] [in a new window]   Fig. 3. ML120B inhibits kinase activity in cells. HeLa cells were preincubated with ML120B for 1 h and subjected to TNF (30 ng/ml) stimulation. Total cell lysates were collected for Western blot. A, TNF can induce IB phosphorylation and degradation in 5 to 20 min. B, ML120B concentration-dependently blocked TNF-induced IB phosphorylation in HeLa cells. C, ML120B concentration-dependently blocked TNF-induced IB degradation in HeLa cells. D, in HeLa cells, ML120B block TNF-induced IB phosphorylation at 5 and 10 min. E, in HeLa cells, ML120B block TNF-induced IB degradation at 10 and 20 min.

View larger version (26K): [in this window] [in a new window]   Fig. 4. ML120B inhibits TNF-induced NF-B p65 cytoplasm to nuclear translocation in HeLa cells. A, image data of NF-B p65 localization by Discovery-1. HeLa cells were seeded in a 96-well plate the day before the experiment. The cells were preincubated with serially diluted ML120B (range from 20 to 0.04 µM) before the simulation with TNF (10 ng/ml). Cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 after 30-min TNF stimulation. Cells were stained for both fluorescein isothiocyanate-labeled p65 and Hoechst following the Cellomics Hit Kit manual. Images were acquired with Discovery-1 system. B, IC50 graph of high-content image analysis by MetaMorph software. Image data acquired with Discovery-1 system were analyzed by MetaMorph software form Universal Imaging Corporation. Quantitative data of NF-B p65 localization in the cells were calculated for IC50 with XLfit.

View larger version (18K): [in this window] [in a new window]   Fig. 5. ML120B dose-dependently inhibits NF-B-dependent transcriptional activity in 293/NF-B luciferase reporter assay but has minimal effect on 293/AP-1-dependent transcriptional activity. 293/NF-B-Luc or 293/AP-1-Luc cells were preincubated with 1:1 serially diluted ML120B (20–0.04 µM) in 96-well plates for 1 h. Cells were stimulated with TNF (0.5 ng/ml) in A or PMA (10 pg/ml)/ionomycin (2 µM) in B for 3 h, respectively. Luciferase activity was measured using cell lysates.

ML120B Inhibits NF-B-Mediated Gene Activation in RA-Relevant Inflammatory Cells. Activated macrophages are known to contribute to synovial inflammation in RA, and IKK has been shown to be a key regulator for macrophage function through activation of the NF-B signaling pathway (Guha and Mackman, 2001). It is noteworthy that anti-TNF therapy such as etanercept and infliximab has proven to be effective therapeutic agents for RA. We therefore investigated the effect of ML120B on TNF release from human PBMCs. Human PBMCs were isolated from normal donors and exposed to LPS in the absence or presence of inhibitor. ML120B concentration-dependently inhibited LPS-stimulated TNF production with an IC₅₀ of 3.3 µM (Fig. 6A). Consistent with the mechanism of IKK inhibition, ML120B also concentration-dependently blocked TNF-induced IB phosphorylation in human PBMCs (Fig. 6C). T cell activation leads to IKK-dependent NF-B up-regulation, which contributes to inflammatory responses in RA. To evaluate the effect of ML120B on T cell signaling pathways, we evaluated CD3/CD28-induced IL-2 production with ML120B treatment in human PBMCs. As indicated in Fig. 6B, ML120B concentration-dependently blocks CD3/CD28-induced IL-2 production with an IC₅₀ of 3.4 µM. The cytotoxicity of ML120B was monitored by measuring LDH release in the supernatant of human PBMC. We found that ML120B did not cause LDH leakage at concentrations up to 20 µM (Fig. 6D), suggesting that the effect of ML120B is not due to cellular toxicity of the inhibitor. The LDH release in ML120B-treated cells is not statistically different compared with DMSO-treated cells (p > 0.01).

View larger version (20K): [in this window] [in a new window]   Fig. 6. ML120B cellular activity in human PBMC assay. A, ML120B concentration-dependently blocks LPS-stimulated TNF production. Fresh isolated human PBMCs were seeded in a 96-well plate at 4 x 105 per well. Cells were preincubated with ML120B (20–0.04 µM) for 1 h and stimulated with LPS (100 ng/ml) for 5 h. Supernatant was collected for TNF ELISA. B, ML120B concentration-dependently blocks CD3/CD28 cross-link-induced IL-2 production. Same as above described, PBMCs were costimulated with CD3 (0.25 µg/ml) and CD28 (0.25 µg/ml) for 5 h. Supernatant was collected for IL-2 ELISA. C, ML120B concentration-dependently blocks TNF-induced IB phosphorylation. Fresh isolated human PBMCs (8 x 106) were seeded in 60-mm dishes. Cells were preincubated with serially diluted ML120B (20, 5, and 1.25 µM) at 5% CO2 at 37°C for 1 h and stimulated with TNF (50 ng/ml) for 5 or 10 min. Total cell lysates were used to determine the level of IB phosphorylation by Western blot. Same blot was probed by housekeeping gene actin to verify the equal loading. D, cytotoxicity (LDH) assay. ML120B cytotoxicity was monitored by LDH release in human PBMC assay. Triton-treated cells (2%) were used as maximal LDH release control. Compound solvent DMSO was used as minimal basal LDH release control.

View larger version (32K): [in this window] [in a new window]   Fig. 7. Effect of ML120B on HFLS. A, ML120B concentration-dependently blocks TNF-induced MCP-1, RANTES, and IL-6 production in HFLS. HFLS (1 x 105) were seeded in a 96-well plate. Cells were preincubated with 1:1 serially diluted ML120B (20–0.04 µM) for 1 h and stimulated with TNF (30 ng/ml) for 16 h. The supernatant was harvested and analyzed for RANTES, MCP-1, and IL-6 production (PerBio; Pierce). B, ML120B concentration-dependently blocks IL-1-induced MCP-1, RANTES, and IL-6 production. Same as above-described in Fig. 6A, except that the cells were stimulated with IL-1 (10 ng/ml) for 16 h. C, ML120B blocks both IL-1- and TNF-induced NF-B p65 binding activity. HFLS were preincubated with serially diluted ML120B (20–0.04 µM) for 1 h. Cells were stimulated with either IL-1 (10 ng/ml) or TNF (30 ng/ml) for 30 min. Nuclear extracts were prepared. NF-B p65 binding activity was quantitatively measured by NF-B DELFIA assay as described.

View this table: [in this window] [in a new window]   TABLE 3 IC50 of ML120B on IL-1 or TNF-stimulated cytokines/chemokines and MMP production

The potential role of MCs in the pathophysiological process of RA has been demonstrated previously (Woolley and Tetlow, 2000; Woolley, 2003). To further investigate the function of IKK in TLR signaling in human MC, we investigated the effect of ML120B on mast cell function with human cord blood PBMC-derived mast cells, characterized by positive toludine blue staining and positive c-Kit expression by FACS (data not shown). In addition, we evaluated the expression pattern of TLRs in human cord blood-derived mast cells by FACS analysis. Human MCs express both TLR2 (receptor for PGN) and TLR4 (receptor for LPS) but have minimal expression of TLR3 and TLR9 (Fig. 8). Purified LPS (gift from Dr. Kate Fitzgerald) was used to avoid potential cross-signaling through other TLRs from contamination. We used adenoviral-mediated overexpression of a dominant-negative version of IKK (IKK DN) or IB SR to elucidate the functional role of IKK and NF-B in TLR signaling in human MCs. Both IKK DN and IB SR can prevent LPS- or PGN-induced NF-B-dependent cytokine production (IL-1, TNF, and IL-6) (Fig. 9, A and B). Consistent with our findings with the adenoviral-mediated overexpression system, ML120B showed concentration-dependent inhibition of PGN- or LPS-induced IL-1, TNF, and IL-6 production with IC₅₀ values ranging from 2.2 to 5.6 µM (Fig. 9, C and D). p values from t test were used to analyze the statistical differences.

View larger version (11K): [in this window] [in a new window]   Fig. 8. TLR expression in human cord blood-derived mast cells. PBMCs were freshly isolated from human cord blood (Cambrex) and in vitro differentiated into mature mast cells as described in Materials and Methods. The maturity of mast cells was monitored by toluidine blue staining and c-Kit expression on cell surface by FACS (data not shown). The expression of TLR was tested by FACS analysis with specific antibody to TLR 2, TLR 4, TLR 3, and TLR 9. Human cord blood-derived mast cells express both TLR 4 (receptor for LPS) and TLR 2 (receptor for PGN) but have minimum expression of TLR 3 and TLR 9.

View larger version (35K): [in this window] [in a new window]   Fig. 9. Role of IKK in human mast cell function. A, 4 x 105 matured mast cells were infected with optimized adenovirus titer (m.o.i.). The similar infection rate for vector alone (GFP), IKK wt, IKK DN, and IB SR was confirmed with GFP expression. After 24-h infection, cells were then stimulated with LPS (10 ng/ml) for 16 h. The supernatant was harvested and analyzed for IL-1, TNF, and IL-6 production (PerBio; Pierce). p values were used to analysis the statistical differences. ****, p < 0.001; ***, p < 0.005; **, p < 0.01; *, p < 0.05. B, same as A, after 24-h infection, cells were stimulated with PGN (100 µg/ml) for 16 h. The supernatant was harvested and analyzed for IL-1, TNF, and IL-6 production (PerBio; Pierce). p values definition is same as Fig. 8A. C, human MCs were seeded in a 96-well plate and preincubated with 1:1 serially diluted ML120B (20–0.04 µM) for 1 h. Cells were stimulated with LPS (10 ng/ml) or PGN (100 µg/ml) overnight. The supernatant was collected for cytokine profiling analysis (PerBio; Pierce). The data were expressed as percentage inhibition of cytokine production. The IC50 values were calculated with Excel XLFit program. D, summary of LPS- or PGN-stimulated IL-1, TNF, and IL-6 production in human cord blood-derived mast cells. IC50 results are expressed as the mean ± S.D. of three different experiments.

Finally, chondrocyte activation is a known contributor to joint inflammation and destruction in RA, and it has been shown that IL-1-mediated chondrocyte activation leads to production of MMPs and other mediators (Fernandes et al., 2002; Abramson, 2004). We used ML120B to evaluate the role of IKK in IL-1-mediated signaling in the human chondrocyte cell line SW1353. ML120B concentration-dependently inhibited IL-1-induced MMP13 and MMP1 production with the IC₅₀ of 0.9 and 1.2 µM, respectively (Fig. 10A). In addition, IL-1-stimulated PGE₂ production was also blocked by ML120B with an IC₅₀ of 1.7 µM (Fig. 10B).

View larger version (13K): [in this window] [in a new window]   Fig. 10. Effect of ML120B on human chondrocyte activities. A, ML120B concentration-dependently blocks IL-1-stimulated MMP13 and MMP1 production in SW1353. Cells were preincubated with 1:1 serially diluted ML120B (20–0.04 µM) for 1 h and stimulated with IL-1 (10 ng/ml) for 24 h. The supernatant was harvested for MMP1 and MMP13 ELISA. B, ML120B concentration-dependently blocks IL-1-induced PGE2 production in SW1353. Same as above described in A, the supernatant was also collected for PGE2 ELISA.

	Discussion

Top Abstract Materials and Methods Results Discussion References

A chemical screening effort using the endogenous IKK complex allowed us to identify -carboline derivatives as novel IKK inhibitors (Castro et al., 2003). Lead optimization led to the identification of ML120B, a potent ATP-competitive inhibitor of IKK. ML120B selectively inhibits only IKK kinase activity when screened against a panel of 30 other kinases. In addition, ML120B does not inhibit the kinase activity of the related proteins IKK or IKK. Furthermore, in a panel of cellular pathway selectivity reporter assays, ML120B only showed an inhibitory effect on the NF-B reporter or reporters that contain an NF-B element in their promoter region (IL-8 and ELAM). Compared with the first-generation -carboline compound PS1145, ML120B has been shown to be a selective inhibitor specific to the NF-B pathway. Thus, ML120B is a useful tool to evaluate the effects of IKK inhibition on the activation of the NF-B pathway in a variety of cell-based systems relevant to RA.

To determine whether IKK activation can be blocked by ML120B in cells, we tested the inhibitory effect of ML120B on IB phosphorylation, on nuclear translocation of NF-B, and on transcriptional regulation. ML120B inhibited TNF-induced IB phosphorylation and degradation in HeLa cells and inhibited nuclear translocation of NF-B with an IC₅₀ of 2.4 µM. ML120B also concentration-dependently blocked TNF-induced NF-B DNA binding activity.

The cellular activity and selectivity of ML120B was further evaluated at the transcription level using NF-B and AP-1 luciferase reporter assays. ML120B selectively inhibits NF-B activity but does not inhibit AP-1 activity. It has been shown that cytokine-activated IKK is essential for NF-B activation (Mercurio et al., 1997). LPS-induced cytokine production in human monocytes and T cell receptor-mediated IL-2 production in T cells are both IKK-dependent (O'Connell et al., 1998). As expected, ML120B inhibited both LPS-stimulated TNF production and CD3/CD28-costimulated IL-2 production in human PBMCs with similar IC₅₀ values around 3 µM. Overall, the data demonstrated that ML120B is a selective IKK inhibitor that blocks IB phosphorylation, nuclear translocation, and NF-B-mediated transcription.

RA is a chronic autoimmune disease characterized by synovitis and bone destruction (Gravallese, 2002). Multiple lines of evidence suggest that several cell types play critical roles in the pathophysiological process of RA. We evaluated HFLS, mast cells, and chondrocytes for ML120B-mediated inhibition of NF-B-dependent responses. HFLS play a critical role in the process of cartilage and bone erosion in RA, presumably via the synthesis and secretion of inflammatory mediators, including IL-6 and IL-8 (Georganas et al., 2000). In vitro IKK blockade with a dominant-negative adenoviral construct inhibited IL-1- or TNF-stimulated IL-6, IL-8, and intercellular adhesion molecule-1 production (Aupperle et al., 2001). In our study, ML120B inhibited TNF- or IL-1-induced IL-6 or IL-8 production in HFLS with IC₅₀ values ranging from 5.7 to 14.5 µM (Table 3). Several lines of evidence indicate that NF-B and MAP kinase/AP-1 pathways are both involved in IL-6 and IL-8 expression in HFLS (Neff et al., 2001) and that cross-talk exists between IL-1 and IL-6 signaling (Deon et al., 2001). Therefore, blocking NF-B with a selective IKK inhibitor may only partially inhibit IL-6 or IL-8 production induced by TNF or IL-1 in HFLS.

Several studies have examined the pathogenic role of chemokine and chemokine receptor interactions in RA (Nanki et al., 2001). We report here for the first time that in HFLS, both RANTES and MCP-1 production induced by TNF or IL-1 are IKK/NF-B-dependent. The selective IKK inhibitor ML120B concentration-dependently blocked TNF- or IL-1-induced RANTES and MCP-1 production with IC₅₀ values ranging from 0.7 to 1.8 µM (Table 3). We found ML120B is more potent in blocking the RANTES and MCP-1 production than its effect on blocking IL-6 and IL-8 production (Table 3). Pharmacia Corporation's IKK inhibitor SC514 inhibits IL-1-stimulated IL-6 and IL-8 production in HFLS with an IC₅₀ of 20 µM (Kishore et al., 2003). Compared with the first generation -carboline IKK inhibitor PS1145 and other classes of IKK inhibitors, ML120B is a highly selective, potent inhibitor. In a separate report, we demonstrated that ML120B was efficacious in an experimental model of RA. The oral administration of ML120B dose-dependently inhibited paw swelling and offered significant protection from arthritis-induced body weight loss, cartilage, and bone erosion (L. Schopf, A. Savinainen, K. Anderson, J. Kujawa, M. DuPont, M. Silva, E. Siebert, S. Chandra, J. Morgan, P. Gangurde, et al., unpublished data). Considering the pivotal role of HFLS in the pathophysiology of RA, the inhibitory effect of ML120B on RANTES, MCP-1, IL-6, and IL-8 production may directly contribute to the in vivo efficacy of the compound.

Active arthritis is associated with increased cell infiltration, as well as expression of proinflammatory cytokines and MMPs (Smeets et al., 2003). ML120B concentration-dependently blocks TNF- or IL-1-induced MMP13, MMP3, and MMP1 production. Results from two to three donors are summarized in Table 3. These data suggest that IKK inhibition may play a dominant role in protecting joint disruption and blockade of inflammatory cell migration in RA joints.

The mast cell is a tissue-based inflammatory cell of bone marrow origin. Mast cells respond to signals of innate and acquired immunity with the immediate and delayed release of inflammatory mediators (Taylor and Metcalfe, 2001). The mast cell is now considered to play a pivotal role not only in allergic reactions but also in a number of other inflammatory disorders (Stevens and Austen, 1989; Boyce, 2003, 2004). A potential role for mast cells in RA has also been highlighted recently (Benoist and Mathis, 2002; Lee et al., 2002; Woolley, 2003), and it has been suggested that mast cells provide a critical cellular link between soluble factors and the synovial eruption through activation of cytokine production upon activation. In addition, cytokine production by mast cells has been linked to NF-B-mediated events (Boyce, 2004). We therefore evaluated ML120B for inhibition of mast cell cytokine production in response to inflammatory initiators. The TLR family is the essential recognition and signaling component of mammalian host defense (Akira and Sato, 2003). TLRs are responsible for the production of inflammatory cytokines in bone marrow-derived mast cells (Stassen et al., 2001). Human cord blood PBMCs can be differentiated in vitro into mast cells (Hsieh et al., 2001). We studied the expression of TLR in this cell type by FACS. Human cord blood-derived mast cells express both TLR 2 and TLR 4 but have minimal expression of TLR 3 and TLR 9. We used adenoviral overexpression of a dominant-negative form of IKK (IKK DN) and IB SR to study the function of IKK/NF-B in TLR signaling. Either LPS- or PGN-induced IL-1, TNF, and IL-6 production was abolished by IKK DN or IB SR. In line with this finding, the selective IKK inhibitor ML120B had similar effects on human MCs. ML120B concentration-dependently inhibited LPS- or PGN-induced IL-1, TNF, and IL-6 production with IC₅₀ values of 2.2 to 5.6 µM. Our results indicate that inhibition of IKK may have a beneficial effect on attenuating local inflammation through the direct blockade of mast cell activation. Interestingly, in the same experiment we found that IL-4 and IL-13 production in MC is not affected by ML120B (data not shown), indicating that these two cytokines may use an NF-B-independent regulatory mechanism in human MCs.

Activated chondrocytes are also thought to play an important role in joint destruction in RA. MMPs, a family of zinc-dependent enzymes, play a prominent role in matrix degradation. Collagenases (MMP1, MMP13) and stromelysins (MMP3) are increased in RA synovium/cartilage (Close, 2001). IL-1 stimulates the release of degrading enzymes by fibroblast-like synoviocytes at the cartilage-pannus interface. At the same time, IL-1 may also activate chondrocytes to release these enzymes, which contributes to the cartilage destruction at sites distant to the pannus. ML120B blocked IL-1-induced MMP13 and MMP1 production in SW1353 cells with IC₅₀ values of 0.9 and 1.2 µM, respectively, suggesting that chondrocytes may be a suitable cell target for IKK inhibition in RA. Recent evidence suggests that cyclo-oxygenase (COX-2), a NF-B-mediated gene product, is a mediator of angiogenesis, and COX-2 activity is known to be up-regulated in the rheumatoid arthritis synovium (Woods et al., 2003). Activation of COX-2 leads to the production of the proinflammatory mediator PGE_2. We investigated the effects of ML120B in IL-1-stimulated PGE₂ production in human SW1353 cells and found that ML120B inhibited IL-1-induced PGE₂ with an IC₅₀ of 1.7 µM. These data suggest a potent inhibitory effect of ML120B on chondrocyte activation and cartilage degradation.

RA is a chronic progressive inflammatory disease of the joint, involving several cell types thought to play key roles in the abnormal immune response, synovial hyperplasia, and joint destruction observed in the course of the disease. These cellular processes are controlled through production of several molecular mediators, including cytokines and chemokines, and it is likely that NF-B is a key transcription factor regulating this inflammatory response. Based on the critical role that IKK plays in cytokine-mediated NF-B activation, targeting IKK represents a novel approach for the treatment of RA. We have developed ML120B, a potent and selective inhibitor of IKK that is specific to the NF-B pathway. ML120B has shown consistent inhibitory effects toward key cell types and inflammatory mediators that are involved in the pathology and progression of RA. The results of these studies suggest a potential use of this class of IKK inhibitors as new therapeutic agents in the treatment of RA.

	Acknowledgements

 
We are deeply grateful to Dr. Margaret Read (Infinity Pharmaceuticals, Inc., Boston, MA) for kind support, helpful discussion, and critical review of the manuscript. Purified LPS for human mast cell study was a gift from Dr. Kate Fitzgerald. We also thank Dr. Philip A. Barker for the adenovirus constructs of IKK wt, IKK DN, and IB SR. We thank biostatistician Mike Pickard (Computational Sciences, Millennium Pharmaceuticals, Inc., Cambridge, MA) for statistical analysis of the data.

	Footnotes

 
This work was presented as a poster in Keystone Symposia NF-B: Biology and Pathology. UT, 2004 [Wen D, Gangurde P, Morgan JG, Nong Y, Savinainen A, Kujawa J, Schopf L, Hepperle M, Harriman G, Jaffee B, et al. (2004) NF-B regulation by IKK in rheumatoid arthritis Poster 365.].

ML120B was covered in the published Parent Cooperation Treaty patent application WO 2004092167: Hepperle ME, Liu JF, Soucy F, Ye Y, Murray RS, Prakash R, Little JD, Castro A, Mazdiyasni H, Fleming PE, et al. (2004) inventors, Millennium Pharmaceuticals, Inc., assignee. Preparation of substituted -carboline IB kinase 2 (IKK-2) inhibitors as potential anti-inflammatory, immunomodulatory, or anticancer agents.

doi:10.1124/jpet.105.097584.

ABBREVIATIONS: NF-B, nuclear factor B; RA, rheumatoid arthritis; TNF, tumor necrosis factor; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated on activation, normal T cell expressed and secreted; MMP, matrix metalloproteinase; IKK, IB kinase; ML120B, N-(6-chloro-7-methoxy-9H--carbolin-8-yl)-2-methylnicotinamide; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; HFLS, human fibroblast-like synoviocyte(s); MC, mast cell; PGE, prostaglandin E; BSA, bovine serum albumin; PS1145, N-(6-chloro-9H--carbolin-8-yl) nicotinamide; DMSO, dimethyl sulfoxide; PMA, phorbol myristate acetate; PGN, peptidoglycan; GST, glutathione S-transferase; AP-1, activator protein-1; MEKK, mitogen-activated protein kinase kinase kinase; PKC, protein kinase C; FBS, fetal bovine serum; DMEM, Dulbecco's modified Eagle's medium; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence-activated cell sorting; PE, phosphatidylethanolamine; TLR, toll-like receptor; wt, wild type; DN, dominant-negative; SR, super-repressor; GFP, green fluorescent protein; ELAM, endothelial cell leukocyte adhesion molecule (E-selectin); LDH, lactate dehydrogenase; MAP, mitogen-activated protein; COX, cyclooxygenase; m.o.i., multiplicity of infection.

Address correspondence to: Danyi Wen, Inflammation Department, Millennium Pharmaceuticals, Inc., 35 Landsdowne Street, Cambridge, MA 02139. E-mail: wen{at}mpi.com

	References

Top Abstract Materials and Methods Results Discussion References

 

Abramson SB (2004) Inflammation in osteoarthritis. J Rheumatol Suppl 70: 70–76.[Free Full Text]

Akira S and Sato S (2003) Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 35: 555–562.[CrossRef][Medline]

Aupperle K, Bennett B, Han Z, Boyle D, Manning A, and Firestein G (2001) NF-B regulation by IB kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 166: 2705–2711.[Abstract/Free Full Text]

Baeuerle PA and Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141–179.[Medline]

Benoist C and Mathis D (2002) Mast cells in autoimmune disease. Nature (Lond) 420: 875–878.[CrossRef][Medline]

Bhakar AL, Tannis LL, Zeindler C, Russo MP, Jobin C, Park DS, MacPherson S, and Barker PA (2002) Constitutive nuclear factor-B activity is required for central neuron survival. J Neurosci 22: 8466–8475.[Abstract/Free Full Text]

Boyce JA (2003) Mast cells: beyond IgE. J Allergy Clin Immunol 111: 24–32.[CrossRef][Medline]

Boyce JA (2004) The biology of the mast cell. Allergy Asthma Proc 25: 27–30.[Medline]

Casola A, Garofalo RP, Jamaluddin M, Vlahopoulos S, and Brasier AR (2000) Requirement of a novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression. J Immunol 164: 5944–5951.[Abstract/Free Full Text]

Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, and Adams J (2003) Novel IKK inhibitors: -carbolines. Bioorg Med Chem Lett 13: 2419–2422.[CrossRef][Medline]

Chen ZJ, Parent L, and Maniatis T (1996) Site-specific phosphorylation of IB by a novel ubiquitination-dependent protein kinase activity. Cell 84: 853–862.[CrossRef][Medline]

Cheong R, Bergmann A, Werner SL, Regal J, Hoffmann A, and Levchenko A (2005) Transient IKK activity mediates NF-B temporal dynamics in response to a wide range of TNF doses. J Biol Chem 281: 2945–2950.

Close DR (2001) Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 60 (Suppl 3): iii62–iii67.[Abstract/Free Full Text]

Covert MW, Leung TH, Gaston JE, and Baltimore D (2005) Achieving stability of lipopolysaccharide-induced NF-B activation. Science (Wash DC) 309: 1854–1857.[Abstract/Free Full Text]

Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, Krause A, and Ivashkiv LB (2001) Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol 167: 5395–5403.[Abstract/Free Full Text]

Fernandes JC, Martel-Pelletier J, and Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237–246.[Medline]

Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, and Pope RM (2000) Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-B but not C/EBP or c-Jun. J Immunol 165: 7199–7206.[Abstract/Free Full Text]

Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61 (Suppl 2): ii84–ii86.[Abstract/Free Full Text]

Guha M and Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13: 85–94.[CrossRef][Medline]

Hammaker D, Sweeney S, and Firestein GS (2003) Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 62 (Suppl 2): ii86–ii89.[Abstract/Free Full Text]

Hsieh FH, Lam BK, Penrose JF, Austen KF, and Boyce JA (2001) T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med 193: 123–133.[Abstract/Free Full Text]

Karin M (1999) How NF-B is activated: the role of the IB kinase (IKK) complex. Oncogene 18: 6867–6874.[CrossRef][Medline]

Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, et al. (2003) A selective IKK-2 inhibitor blocks NF-B-dependent gene expression in interleukin-1 -stimulated synovial fibroblasts. J Biol Chem 278: 32861–32871.[Abstract/Free Full Text]

Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, and Brenner MB (2002) Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science (Wash DC) 297: 1689–1692.[Abstract/Free Full Text]

Lee FS, Hagler J, Chen ZJ, and Maniatis T (1997) Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88: 213–222.[CrossRef][Medline]

Lee FS, Peters RT, Dang LC, and Maniatis T (1998) MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci USA 95: 9319–9324.[Abstract/Free Full Text]

Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, et al. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (Wash DC) 278: 860–866.[Abstract/Free Full Text]

Nanki T, Nagasaka K, Hayashida K, Saita Y, and Miyasaka N (2001) Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 167: 5381–5385.[Abstract/Free Full Text]

Neff L, Zeisel M, Sibilia J, Scholler-Guinard M, Klein JP, and Wachsmann D (2001) NF-B and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci. Cell Microbiol 3: 703–712.[CrossRef][Medline]

O'Connell MA, Bennett BL, Mercurio F, Manning AM, and Mackman N (1998) Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem 273: 30410–30414.[Abstract/Free Full Text]

Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, and Tak PP (2003) Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 62: 635–638.[Abstract/Free Full Text]

Stassen M, Muller C, Arnold M, Hultner L, Klein-Hessling S, Neudorfl C, Reineke T, Serfling E, and Schmitt E (2001) IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-B is decisively involved in the expression of IL-9. J Immunol 166: 4391–4398.[Abstract/Free Full Text]

Stevens RL and Austen KF (1989) Recent advances in the cellular and molecular biology of mast cells. Immunol Today 10: 381–386.[CrossRef][Medline]

Taylor ML and Metcalfe DD (2001) Mast cells in allergy and host defense. Allergy Asthma Proc 22: 115–119.[CrossRef][Medline]

Werner SL, Barken D, and Hoffmann A (2005) Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science (Wash DC) 309: 1857–1861.[Abstract/Free Full Text]

Woods JM, Mogollon A, Amin MA, Martinez RJ, and Koch AE (2003) The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74: 282–290.[CrossRef][Medline]

Woolley DE (2003) The mast cell in inflammatory arthritis. N Engl J Med 348: 1709–1711.[Free Full Text]

Woolley DE and Tetlow LC (2000) Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2: 65–74.[CrossRef][Medline]

Yamamoto Y and Gaynor RB (2001) Therapeutic potential of inhibition of the NF-B pathway in the treatment of inflammation and cancer. J Clin Investig 107: 135–142.[Medline]

Yamamoto Y and Gaynor RB (2004) IkappaB kinases: key regulators of the NF-B pathway. Trends Biochem Sci 29: 72–79.[CrossRef][Medline]

This article has been cited by other articles:

				T. Hideshima, D. Chauhan, T. Kiziltepe, H. Ikeda, Y. Okawa, K. Podar, N. Raje, A. Protopopov, N. C. Munshi, P. G. Richardson, et al. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications Blood, May 21, 2009; 113(21): 5228 - 5236. [Abstract] [Full Text] [PDF]

				G. Mbalaviele, C. D. Sommers, S. L. Bonar, S. Mathialagan, J. F. Schindler, J. A. Guzova, A. F. Shaffer, M. A. Melton, L. J. Christine, C. S. Tripp, et al. A Novel, Highly Selective, Tight Binding I{kappa}B Kinase-2 (IKK-2) Inhibitor: A Tool to Correlate IKK-2 Activity to the Fate and Functions of the Components of the Nuclear Factor-{kappa}B Pathway in Arthritis-Relevant Cells and Animal Models J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 14 - 25. [Abstract] [Full Text] [PDF]

				L. T. Lam, R. E. Davis, V. N. Ngo, G. Lenz, G. Wright, W. Xu, H. Zhao, X. Yu, L. Dang, and L. M. Staudt Compensatory IKK{alpha} activation of classical NF-{kappa}B signaling during IKK{beta} inhibition identified by an RNA interference sensitization screen PNAS, December 30, 2008; 105(52): 20798 - 20803. [Abstract] [Full Text] [PDF]

				D.-F. Lee and M.-C. Hung Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy Clin. Cancer Res., September 15, 2008; 14(18): 5656 - 5662. [Abstract] [Full Text] [PDF]

				H. P. Carroll, V. Paunovic, and M. Gadina Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity Rheumatology, September 1, 2008; 47(9): 1269 - 1277. [Abstract] [Full Text] [PDF]

				H. C. Owen, S. J. Roberts, S. F. Ahmed, and C. Farquharson Dexamethasone-induced expression of the glucocorticoid response gene lipocalin 2 in chondrocytes Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1023 - E1034. [Abstract] [Full Text] [PDF]

				R. Newton, N. S. Holden, M. C. Catley, W. Oyelusi, R. Leigh, D. Proud, and P. J. Barnes Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule I{kappa}B Kinase Inhibitors J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 734 - 742. [Abstract] [Full Text] [PDF]

				I Strickland and S Ghosh Use of cell permeable NBD peptides for suppression of inflammation Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii75 - iii82. [Abstract] [Full Text] [PDF]

				M. C. Catley, M. B. Sukkar, K. F. Chung, B. Jaffee, S.-M. Liao, A. J. Coyle, E.-B. Haddad, P. J. Barnes, and R. Newton Validation of the Anti-Inflammatory Properties of Small-Molecule I{kappa}B Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle Mol. Pharmacol., August 1, 2006; 70(2): 697 - 705. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.105.097584v1 jpet.105.097584v2 317/3/989    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wen, D. Articles by Xu, Y. Search for Related Content PubMed PubMed Citation Articles by Wen, D. Articles by Xu, Y. Pubmed/NCBI databases Compound via MeSH Substance via MeSH